SCHEMBL7812114

SCHEMBL7812114

Cn1[c]nc2c(Cl)cc(C(F)(F)F)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 2/20 0.38
▸ PDE10A Q9Y233 1/20 0.38
▸ GABRA2 P47869 9/20 0.37
▸ GABRB2 P47870 9/20 0.37
▸ GABRB3 P28472 9/20 0.37
▸ GABRP O00591 3/20 0.35
▸ GABRD O14764 3/20 0.35
▸ GABRA1 P14867 3/20 0.35
▸ GABRB1 P18505 3/20 0.35
▸ GABRG2 P18507 3/20 0.35
▸ GABRA5 P31644 3/20 0.35
▸ GABRA3 P34903 3/20 0.35
▸ GABRA4 P48169 3/20 0.35
▸ GABRE P78334 3/20 0.35
▸ GABRA6 Q16445 3/20 0.35
▸ GABRG1 Q8N1C3 3/20 0.35
▸ GABRG3 Q99928 3/20 0.35
▸ GABRQ Q9UN88 3/20 0.35
▸ POLB P06746 1/20 0.34
▸ KIF20B Q96Q89 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7812344 0.82 GRM2 (0.42) GABRA2GABRB2GABRB3GABRPGABRD
SCHEMBL7805418 0.75 GABRA2 (0.36) GABRA2GABRB2GABRB3GABRPGABRD
SCHEMBL7810834 0.71 KIF11 (0.42) PDE2APDE10A
SCHEMBL22954114 0.70 PKM (0.49) PDE2APDE10AGABRA2GABRB2GABRB3
SCHEMBL3651143 0.68 PKM (0.50) PDE2APDE10A
SCHEMBL7818166 0.66 GRM2 (0.40) HSD11B1
SCHEMBL2791778 0.65 PDE2A (0.53) PDE2APDE10AGABRA2GABRB2GABRB3
SCHEMBL5982858 0.65 PDE10A (0.31) PDE2APDE10A
SCHEMBL5006009 0.64 KIF20B (0.35) PDE2APDE10AGABRA2GABRB2GABRB3
SCHEMBL6665560 0.64 CBFB (0.42) GABRA2GABRB2GABRB3GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 — — EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 — — US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 — — EP disclosed
Send feedback